Expert Interview
A second look: Discussing Silence Therapeutics' divesiran and Protagonist's rusfertide as potential therapies in Polycythemia Vera
Ticker(s): SLN, PTGXInstitution: Moffitt Cancer Center
- Hematologist/Oncologist, and Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology.
- Currently manages 200-250 patients with myelofibrosis and is very familiar with the literature to date on Morphosys' pelabresib and noted he "was not involved in the phase 2 MANIFEST, but was involved in MANIFEST-2".
- Primary investigator on a number of myelofibrosis clinical trials including MANIFEST-2 (pelabresib), MOMENTUM (momelotinib), others sponsored by Janssen, Novartis, and Geron, and numerous other clinical trials.
How are you currently treating PV?
Added By: wilson_adminWhat are your opinions on the clinical data presented on divesiran?
Added By: wilson_adminWhat are your opinions on the clinical data presented on rusfertide?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
